|Prenatal therapy for fetal growth restriction.|
|PMID: 16721109 Owner: NLM Status: MEDLINE|
|The choice of therapy for fetal growth restriction (FGR) depends on the nature of the insult that led to the development of FGR. Many etiologic factors are either not amenable to therapy or fetal growth has not been improved by treatments that benefit the mother. Many therapeutic approaches have been used to improve fetal condition. None of the approaches have been of value in a consistent manner. We present the numerous approaches, and their rationale for their use, that have been tried to treat the growth impaired fetus. The evidence from the randomized clinical trials is summarized and their conclusions given.|
|Reinaldo Figueroa; Dev Maulik|
Related Documents :
|2663089 - Endocrine control of fetal growth.
8017949 - Degradation of pyrene at low defined oxygen concentrations by a mycobacterium sp.
24804149 - Clinico hemato biochemical findings, clinical management, and production performance of...
64859 - Concentrations of pregnancy-specific beta 1-glycoprotein in maternal blood in normal pr...
15333699 - Maternal nutrition and fetal development.
3892389 - Intrauterine growth in twin pregnancies: prediction of fetal growth retardation.
18633329 - Drinking water disinfection by-product exposure and duration of gestation.
23548219 - Effect of intraumbilical vein oxytocin injection on third stage of labor.
23168759 - Epidemiology, natural history, progression, and postnatal outcome of severe fetal ventr...
|Type: Journal Article; Review|
|Title: Clinical obstetrics and gynecology Volume: 49 ISSN: 0009-9201 ISO Abbreviation: Clin Obstet Gynecol Publication Date: 2006 Jun|
|Created Date: 2006-05-24 Completed Date: 2008-01-16 Revised Date: 2009-11-11|
Medline Journal Info:
|Nlm Unique ID: 0070014 Medline TA: Clin Obstet Gynecol Country: United States|
|Languages: eng Pagination: 308-19 Citation Subset: IM|
|Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Winthrop University Hospital, Mineola, New York, USA. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
administration & dosage
Aspirin / administration & dosage
Calcium Channel Blockers / administration & dosage
Calcium, Dietary / administration & dosage
Fetal Growth Retardation / drug therapy, prevention & control, therapy*
Fish Oils / administration & dosage
Folic Acid / administration & dosage
Iron Compounds / administration & dosage
Lower Body Negative Pressure
Magnesium Compounds / administration & dosage
Meta-Analysis as Topic
Nitric Oxide Donors / administration & dosage
Oxygen Inhalation Therapy
Plasma Substitutes / administration & dosage
Randomized Controlled Trials as Topic
Vitamins / administration & dosage
Zinc Compounds / administration & dosage
|0/Adrenergic beta-Agonists; 0/Calcium Channel Blockers; 0/Calcium, Dietary; 0/Fish Oils; 0/Iron Compounds; 0/Magnesium Compounds; 0/Nitric Oxide Donors; 0/Plasma Substitutes; 0/Vitamins; 0/Zinc Compounds; 50-78-2/Aspirin; 59-30-3/Folic Acid|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sonographic diagnosis of fetal growth restriction.
Next Document: Management of fetal growth restriction: an evidence-based approach.